At a glance
ClinicalIndex Comparison RecordStandardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.
Physiological Study to Predict Successful Sleep Apnea Treatment With Acetazolamide in Heart Failure Patients
In Brief
A clinical study evaluating Acetazolamide and Placebo for Heart Failures. Completed, enrolled 29 participants across 1 site.
Detailed Summary
The ultimate goal is to improve our understanding of the pathophysiology and resistance to effective treatment of sleep disordered breathing in patients with heart failure, with a focus on selecting patients that will benefit specifically from acetazolamide treatment. The study addresses three primary hypotheses: 1) Acetazolamide treatment will reduce the apnea-hypopnea index and improve markers of heart-failure severity in heart-failure patients with sleep apnea. 2) Acetazolamide will provide the greatest improvement in patients with the most severe ventilatory control instability (strongest chemoreflex response to carbon dioxide; highest loop gain). 3) Acetazolamide will act primarily via stabilizing ventilatory control (reducing loop gain), rather than via improvement to upper airway anatomy, pulmonary congestion, and cardiac function.
Study Details
Timeline
Interventions
4 mg/kg, once daily before bed, for 7 days
4 mg/kg, once daily before bed, for 7 days